Acyclovir Recommendations for Varicella Management

Healthy Children – Household Contacts

• Secondary household contacts of varicella are at higher risk for moderate‑to‑severe disease, so oral acyclovir may be considered for this group. 1

Timing of Therapy

• Therapeutic benefit of acyclovir requires initiation within 24 hours of rash onset; treatment started later shows no efficacy. 1

Adolescents and Adults

• The CDC recommends that individuals older than 12 years who have risk factors for moderate‑to‑severe varicella be offered oral acyclovir. 1

Immunocompromised Patients – Intravenous Therapy

• Intravenous acyclovir is the standard of care for immunocompromised patients with varicella and has been shown to lower morbidity and mortality when administered within 24 hours of rash onset. 1

Critical Pitfalls – Treatment Delay

• Delaying acyclovir beyond the 24‑hour window eliminates its efficacy, reinforcing the need for prompt initiation. 1

Critical Pitfalls – Post‑Exposure Prophylaxis

• Acyclovir should not be used for post‑exposure prophylaxis in otherwise healthy persons; vaccination is the preferred strategy, while immunocompromised contacts should receive VariZIG instead. 1

Critical Pitfalls – Effectiveness in Healthy Children

• In otherwise healthy children, oral acyclovir does not decrease transmission, shorten school‑absence duration, or lower acute complication rates. 1

Antiviral Recommendations for Chickenpox

Adult Treatment

• The Centers for Disease Control and Prevention (CDC) recommends oral acyclovir, not valacyclovir, for adults with chickenpox when treatment is indicated, and it should be started within 24 hours of rash onset【2】【3】.

Risk‑Based Considerations in Adolescents and Adults

• The CDC advises that oral acyclovir be considered for otherwise healthy individuals older than 12 years who are at increased risk for moderate to severe varicella infection【2】【3】.

Pediatric Treatment Options

• According to CDC recommendations, oral acyclovir at a dose of 20 mg/kg administered four times daily (maximum 800 mg per dose) is FDA‑approved and effective for treating chickenpox in children【2】【3】.